دورية أكاديمية
أعرض في EDS

Sentinel Node Status is the Most Important Prognostic Information for Clinical Stage IIB and IIC Melanoma Patients.

التفاصيل البيبلوغرافية
العنوان: Sentinel Node Status is the Most Important Prognostic Information for Clinical Stage IIB and IIC Melanoma Patients.
المؤلفون: Fonseca IB; Surgical Oncology Residence Program, A. C. Camargo Cancer Center, São Paulo, SP, Brazil., Lindote MVN; Surgical Oncology Residence Program, A. C. Camargo Cancer Center, São Paulo, SP, Brazil., Monteiro MR; Surgical Oncology Residence Program, A. C. Camargo Cancer Center, São Paulo, SP, Brazil., Doria Filho E; Department of Surgical Oncology, Clínica AMO, Salvador, BA, Brazil., Pinto CAL; Department of Pathology, A. C. Camargo Cancer Center, São Paulo, SP, Brazil., Jafelicci AS; Skin Cancer Department, A. C. Camargo Cancer Center, São Paulo, SP, Brazil., de Melo Lôbo M; Skin Cancer Department, A. C. Camargo Cancer Center, São Paulo, SP, Brazil., Calsavara VF; Department of Epidemiology and Statistics, A. C. Camargo Cancer Center, São Paulo, SP, Brazil., Bertolli E; Skin Cancer Department, A. C. Camargo Cancer Center, São Paulo, SP, Brazil. ebertolli@hotmail.com., Duprat Neto JP; Skin Cancer Department, A. C. Camargo Cancer Center, São Paulo, SP, Brazil.
المصدر: Annals of surgical oncology [Ann Surg Oncol] 2020 Oct; Vol. 27 (11), pp. 4133-4140. Date of Electronic Publication: 2020 Aug 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2005- : New York, NY : Springer
Original Publication: New York, NY : Raven Press, c1994-
مواضيع طبية MeSH: Melanoma*/surgery , Sentinel Lymph Node*/surgery , Skin Neoplasms*/surgery, Humans ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Sentinel Lymph Node Biopsy
مستخلص: Background: Sentinel node biopsy (SNB) for melanoma patients has been questioned. We aimed to study high-risk stage II melanoma patients who underwent SNB to determine what the prognostic factors regarding recurrence and mortality were, and evaluate how relevant SNB status is in this scenario.
Methods: This was a retrospective analysis of clinical stage IIB/IIC melanoma patients who underwent SNB from 2000 to 2015 in a single institution. Prognostic factors related to distant recurrence-free survival (DRFS) and melanoma-specific survival (MSS) were assessed from multiple Cox regression. Relevant variables were used to create risk predictor nomograms for DRFS and MSS.
Results: From 1213 SNB, 259 were performed for clinical stage IIB/IIC melanoma patients. SNB status was the most important variable for both endpoints. Patients with positive SNB presented median DRFS of 35.73 months (95% CI 21.38-50.08, SE 7.32) and median MSS of 66.4 months (95% CI 29.76-103.03, SE 18.69), meanwhile both median DRFS and MSS were not achieved for those with negative SNB (logrank < 0.0001). Both nomograms have been internally validated and presented adequate calibration (C-index was 0.734 for DRFS and 0.718 for MSS).
Conclusions: SNB status was the most important risk factor in our cohort of clinical stage IIB and IIC patients and, in conjunction with well-established primary tumor characteristics, should not be abandoned. Their use in prognosis for these patients remains extremely useful for daily practice.
References: Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–9. (PMID: 155849010.1001/archsurg.1992.01420040034005)
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609. (PMID: 24521106405888110.1056/NEJMoa1310460)
Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: american society of clinical oncology and society of surgical oncology clinical practice guideline update. Ann Surg Oncol. 2018;25(2):356–77. (PMID: 2923620210.1245/s10434-017-6267-7)
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long G V., Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA A Cancer J Clin. 2017;67(6):472–92.
Madu MF, Wouters MWJM, van Akkooi ACJ. Sentinel node biopsy in melanoma: Current controversies addressed. Eur J Surg Oncol. 2017;43(3):517–33. (PMID: 2759068510.1016/j.ejso.2016.08.007)
Zagarella S. Sentinel lymph node biopsy still provides no benefits for patients with melanoma. Am J Dermatopathol. 2020;00(00):1.
García-Doval I, Espinosa-Pereiro C, Zulaica Gárate A. Biopsia selectiva del ganglio centinela en melanoma: ni utilidad terapéutica, ni es buena para seleccionar los pacientes que podrían beneficiarse de la inmunoterapia adyuvante. Actas Dermosifiliogr. 2020.
Bigby M, Zagarella S, Sladden M, Popescu CM. Time to reconsider the role of sentinel lymph node biopsy in melanoma. J Am Acad Dermatol. 2019;80(4):1168–71. (PMID: 3047131410.1016/j.jaad.2018.11.026)
Sladden M, Zagarella S, Popescu C, Bigby M. No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report. Br J Dermatol. 2015;172(3):566–71. (PMID: 2577624610.1111/bjd.13675)
Verver D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, et al. Risk stratification of sentinel node–positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. Eur J Cancer. 2018;96:25–33. (PMID: 2966059710.1016/j.ejca.2018.02.022)
Bertolli E, Franke V, Calsavara VF, de Macedo MP, Pinto CAL, van Houdt WJ, et al. Validation of a nomogram for non-sentinel node positivity in melanoma patients, and its clinical implications: a Brazilian–Dutch study. Ann Surg Oncol. 2019;26(2):395–405. https://doi.org/10.1245/s10434-018-7038-9 . (PMID: 3045668110.1245/s10434-018-7038-9)
Ipenburg NA, Nieweg OE, Uren RF, Thompson JF. Outcome of melanoma patients who did not proceed to sentinel node biopsy after preoperative lymphoscintigraphy. Ann Surg Oncol. 2017;24(1):117–26. (PMID: 2748035610.1245/s10434-016-5458-y)
Bellomo D, Arias-Mejias SM, Ramana C, Heim JB, Quattrocchi E, Sominidi-Damodaran S, et al. Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. JCO Precis Oncol. 2020;47(4):319–34. (PMID: 10.1200/PO.19.00206)
Bertolli E, de Macedo MP, Calsavara VF, Pinto CAL, Duprat Neto JP. A nomogram to identify high-risk melanoma patients with a negative sentinel lymph node biopsy. J Am Acad Dermatol. 2019;80(3):722–6. (PMID: 3039592010.1016/j.jaad.2018.10.060)
Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob J-J, Hauschild A, et al. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020;16(3):4429–38. (PMID: 10.2217/fon-2019-0666)
Eggermont AMM, Blank CU, Mandala M, Long G V., Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801. (PMID: 2965843010.1056/NEJMoa1802357)
Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, et al. Economic evaluation of single versus combination immuno-oncology therapies: application of a novel modelling approach in metastatic melanoma. Clin Outcomes Res. 2020;12:241–52. (PMID: 10.2147/CEOR.S238725)
Meng Y, Hertel N, Ellis J, Morais E, Johnson H, Philips Z, et al. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. Eur J Heal Econ. 2018;19(8):1163–72. (PMID: 10.1007/s10198-018-0964-4)
Seiger K, Schmults CD, Silk AW, Ruiz ES. Cost and utilization of immunotherapy and targeted therapy for melanoma: cross-sectional analysis in the Medicare population, 2013 and 2015. J Am Acad Dermatol. 2020;82(3):761–4. (PMID: 3162688410.1016/j.jaad.2019.10.023)
Duprat JP, Silva DCP, Coimbra FJF, Lima IAM, Lima ENP, Almeida OM, et al. Sentinel lymph node biopsy in cutaneous melanoma: analysis of 240 consecutive cases. Plast Reconstr Surg 2005;115(7):1944–51. discussion 1952–1953. A. (PMID: 1592384110.1097/01.PRS.0000165279.99067.79)
Bertolli E, De Macedo MP, Pinto CAL, Damascena AS, Molina AS, Ueno PS, et al. Evaluation of melanoma features and their relationship with nodal disease: the importance of the pathological report. Tumori. 2015;101(5):501–5. (PMID: 2598310010.5301/tj.5000298)
Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48(1):73. (PMID: 10.2307/2532740)
Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34(2):187–220.
Steyerberg EW, Harrell FE. Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol. 2016; 69:245–7. (PMID: 2598151910.1016/j.jclinepi.2015.04.005)
D. Schoenfeld. Partial residuals for the proportionnal hazards regression model. Biometrika. 1982;69(1):239–41. (PMID: 10.1093/biomet/69.1.239)
Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–26. (PMID: 10.1093/biomet/81.3.515)
Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22. (PMID: 28591523554838810.1056/NEJMoa1613210)
Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67. (PMID: 2716153910.1016/S1470-2045(16)00141-8)
Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37(32):3000–8. (PMID: 3155706710.1200/JCO.18.02306)
Guidelines N. Cutaneous melanoma. NCCN Clin Pract Guidel Oncol (NCCN Guidel. 2020;v3.2020.
Long G V., Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–23. (PMID: 2889140810.1056/NEJMoa1708539)
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35. (PMID: 2889142310.1056/NEJMoa1709030)
de Melo AC, Wainstein AJA, Buzaid AC, Thuler LCS. Melanoma signature in Brazil. Melanoma Res. 2018;28(6):629–36. (PMID: 3020468410.1097/CMR.0000000000000511)
Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, et al. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer. 2018;104:201–9. (PMID: 3038870010.1016/j.ejca.2018.09.013)
Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55. (PMID: 27717298564854510.1056/NEJMoa1611299)
Bello DM, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, et al. The prognostic significance of sentinel lymph node status for patients with thick melanoma. Ann Surg Oncol. 2016;23(S5):938–45. (PMID: 2752771710.1245/s10434-016-5502-y)
Morera-Sendra N, Tejera-Vaquerizo A, Traves V, Requena C, Bolumar I, Pla A, et al. Value of sentinel lymph node biopsy and adjuvant interferon treatment in thick (> 4 mm) cutaneous melanoma: an observational study. Eur J Dermatol. 2016;26(1):34–48. (PMID: 2702301710.1684/ejd.2015.2693)
Gyorki DE, Sanelli A, Herschtal A, Lazarakis S, McArthur GA, Speakman D, et al. Sentinel lymph node biopsy in T4 melanoma: an important risk-stratification tool. Ann Surg Oncol. 2016;23(2):579–84. (PMID: 2647149110.1245/s10434-015-4894-4)
Ribero S, Osella-Abate S, Sanlorenzo M, Balagna E, Senetta R, Fierro MT, et al. Sentinel lymph node biopsy in thick-melanoma patients (N = 350): what is its prognostic role? Ann Surg Oncol. 2015;22(6):1967–73. (PMID: 2538805910.1245/s10434-014-4211-7)
Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80. (PMID: 25846097446535310.1016/S1470-2045(14)71116-7)
Iasonos A, Schrag D, Raj G V., Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70. (PMID: 1832355910.1200/JCO.2007.12.9791)
Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American joint committee on cancer staging system. Ann Surg Oncol. 2005; 12:282–8. (PMID: 1582767910.1245/ASO.2005.05.016)
MacDonald S, Siever J, Baliski C. Performance of models predicting residual lymph node disease in melanoma patients following sentinel lymph node biopsy. Am J Surg. 2020;219(5):750–5. (PMID: 3222227410.1016/j.amjsurg.2020.02.059)
Oliveira KCS, Ramos IB, Silva JMC, Barra WF, Riggins GJ, Palande V, et al. Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of cancer. Mol Cancer Res. 2020;18(4):517–28. (PMID: 3199646910.1158/1541-7786.MCR-19-0768)
Podlipnik S, Carrera C, Boada A, Richarz NA, López‐Estebaranz JL, Pinedo‐Moraleda F, et al. Early outcome of a 31‐gene expression profile test in 86 AJCC stage IB—II melanoma patients. A prospective multicentre cohort study. J Eur Acad Dermatol Venereol. 2019;33(5):857–62.
Blank CU, Haanen JB, Ribas A, Schumacher TN. The “cancer immunogram.” Science. 2016;352(6286):658–60. (PMID: 2715185210.1126/science.aaf2834)
Naffouuje SA, Naffouje R, Chen J, Salti GI. Validation and enhancement of the clinicopathological melanoma nomogram via incorporation of a molecular marker in the primary tumor. Anticancer Res. 2016;36(12):6603–10. (PMID: 10.21873/anticanres.11266)
تواريخ الأحداث: Date Created: 20200809 Date Completed: 20210505 Latest Revision: 20210505
رمز التحديث: 20231215
DOI: 10.1245/s10434-020-08959-9
PMID: 32767223
قاعدة البيانات: MEDLINE
الوصف
تدمد:1534-4681
DOI:10.1245/s10434-020-08959-9